Suraksha Diagnostic

Suraksha Diagnostic

298.00
-12.40
(-3.99%)
Market Cap
1,552.00 Cr
EPS
5.97
PE Ratio
46.65
Dividend Yield
0.00 %
52 Week High
449.00
52 Week Low
231.00
PB Ratio
7.35
Debt to Equity
0.46
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Dr. Somnath Chatterjee, Promoter, Chairman & Joint Managing Director of Suraksha Diagnostic Limited, purchased 7,800 equity shares through open market purchase on August 18, 2025. The acquisition increased his shareholding from 26,46,968 shares (5.082%) to 26,54,768 shares (5.097%), representing a 0.015% increase in his stake. The company has a paid-up capital of ₹10,41,61,516 consisting of 5,20,80,758 equity shares of ₹2 each. Suraksha Diagnostic is listed on BSE and NSE with scrip code 544293 and symbol SURAKSHA.
positive
Dr. Somnath Chatterjee, Promoter, Chairman & Joint Managing Director of Suraksha Diagnostic Limited, acquired 8,200 equity shares through open market purchase on August 14, 2025. The acquisition increased his shareholding from 26,38,768 shares (5.067%) to 26,46,968 shares (5.082%) of the company's total equity. Suraksha Diagnostic has a paid-up capital of ₹10.42 crore consisting of 5.21 crore equity shares of ₹2 each. The company's shares are listed on BSE and NSE.
positive
Suraksha Diagnostic Reports 18.83% Revenue Growth in Q1 FY26, Expands Genomics CapabilitiesAug 14, 2025
Suraksha Diagnostic Limited reported total income of INR 734.92 million for Q1 FY26, marking an 18.83% year-on-year increase. EBITDA grew 13.51% to INR 246.56 million with a margin of 33.97%, while PAT rose 19.67% to INR 91.75 million. The company expanded its network by adding eight new centers during the quarter, bringing the total to 58 centers. Key developments include acquiring a 63% stake in Fetomat Wellness Private Limited for INR 22 crores in April 2025, marking entry into genomic medicine and pregnancy care services. The company launched Suraksha Genomics, positioning itself as the first complete genomic laboratory facility in Eastern India. Volume growth reached 26% year-on-year, driven by increased B2B partnerships and new center additions. The company closed three underperforming centers and expects to add 15-18 centers in the current fiscal year. Management projects revenue growth guidance of 15% and EBITDA margin of 34-35% for the full year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
3,194.50
#1 26,762.10
52.17
#1 2,554.80
11.28
#1 492
24.30
48.34
1,019.90
10,473.10
69.35
699.70
23.06
144
22.54
46.31
2,014.60
10,436.00
68.52
1,346.30
10.64
146
18.90
43.26
1,124.20
5,957.60
55.86
702.20
20.80
91
60.25
39.98
793.35
2,561.70
31.98
742.70
16.70
78
14.53
44.10
298.00
#6 1,552.00
#5 46.65
#7 255.90
#6 15.11
#7 31
#5 19.48
48.47
1,364.00
1,170.70
23.87
111.60
28.72
48
11.50
40.60
313.20
996.30
#1 10.83
1,170.80
-18.47
-134
-35.12
57.31
276.00
537.40
20.39
147.80
#1 134.60
19
#1 444.44
59.70
189.90
132.30
88.74
41.80
13.28
2
0.00
42.17
Forecast
Actual
Growth Rate
Revenue Growth
15.11 %
Net Income Growth
34.20 %
Cash Flow Change
4.76 %
ROE
14.18 %
ROCE
10.95 %
EBITDA Margin (Avg.)
0.39 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
53
61
53
56
62
68
60
66
74
Expenses
37
39
37
37
40
44
41
46
49
EBITDA
16
21
16
20
22
25
19
20
25
Operating Profit %
28 %
35 %
30 %
34 %
34 %
35 %
31 %
29 %
33 %
Depreciation
8
8
8
8
9
9
9
9
10
Interest
2
3
2
2
2
2
2
2
3
Profit Before Tax
5
11
6
9
11
14
8
9
13
Tax
1
3
2
3
3
4
2
2
3
Net Profit
4
8
5
6
8
10
6
7
9
EPS in ₹
1.17
2.44
0.87
1.22
1.49
1.94
1.18
1.42
1.80

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
171
284
281
300
334
Fixed Assets
119
207
195
212
223
Current Assets
27
63
68
72
47
Capital Work in Progress
0
1
2
1
11
Investments
5
0
0
0
1
Other Assets
47
76
84
87
99
Total Liabilities
171
284
281
300
334
Current Liabilities
25
38
38
39
43
Non Current Liabilities
20
96
87
82
81
Total Equity
126
149
156
179
210
Reserve & Surplus
118
141
147
171
201
Share Capital
9
9
9
9
10

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
-1
-0
-1
0
-0
Investing Activities
-20
-28
-44
-21
-35
-40
Operating Activities
31
24
42
44
61
63
Financing Activities
-10
3
1
-24
-25
-24

Share Holding

% Holding
Jul 2024
Nov 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
72.41 %
61.06 %
48.78 %
48.78 %
48.88 %
FIIs
0.00 %
0.00 %
15.39 %
14.46 %
13.95 %
DIIs
0.00 %
0.00 %
20.44 %
22.05 %
22.37 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
14.08 %
13.52 %
13.08 %
Others
27.59 %
38.94 %
1.31 %
1.19 %
1.71 %
No of Share Holders
10
10
10
87,275
79,670

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Dec 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 Dec 2024 411.35 408.00
08 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Feb 2025 311.80 347.15
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 May 2025 314.65 326.95
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 304.80 290.45
05 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
05 Sept 2025 326.95 302.70

Announcements

Closure of Trading Window5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 05, 2025
Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Clarification On AGM ResolutionSep 04, 2025
Weblink Letter To Shareholders As Per Regulation 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 18, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 18, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 18, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Intimation For Grant Of Employee Stock Options Under SURAKSHA EMPLOYEE STOCK OPTION SCHEME 2024 (ESOP 2024/Scheme)Aug 08, 2025
Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Three Months Ended 30 June 2025Aug 08, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. Friday 08 August 2025Aug 08, 2025
Reg. 34 (1) Annual Report.Aug 07, 2025
Notice Of The 20Th Annual General Meeting (AGM) Of The Company To Be Held On Friday 05 September 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 05, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 25, 2025
Closure of Trading WindowJun 20, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 20, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 20, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 19, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 19, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 06, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 06, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025

Technical Indicators

RSI(14)
Neutral
38.88
ATR(14)
Volatile
9.56
STOCH(9,6)
Neutral
31.79
STOCH RSI(14)
Oversold
6.90
MACD(12,26)
Bearish
-1.33
ADX(14)
Weak Trend
21.02
UO(9)
Bearish
38.64
ROC(12)
Downtrend And Accelerating
-2.92
WillR(14)
Oversold
-92.11